286 related articles for article (PubMed ID: 24185941)
21. Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation.
Swaminathan S; Qiu J; Rupert AW; Hu Z; Higgins J; Dewar RL; Stevens R; Rehm CA; Metcalf JA; Sherman BT; Baseler MW; Lane HC; Imamichi T
PLoS One; 2016; 11(11):e0167091. PubMed ID: 27880829
[TBL] [Abstract][Full Text] [Related]
22. Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.
Dahl V; Peterson J; Spudich S; Lee E; Shacklett BL; Price RW; Palmer S
AIDS; 2013 Apr; 27(7):1145-9. PubMed ID: 23211774
[TBL] [Abstract][Full Text] [Related]
23. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
25. CD4 T-cell regeneration in HIV-1 elite controllers.
Yang Y; Al-Mozaini M; Buzon MJ; Beamon J; Ferrando-Martinez S; Ruiz-Mateos E; Rosenberg ES; Pereyra F; Yu XG; Lichterfeld M
AIDS; 2012 Mar; 26(6):701-6. PubMed ID: 22301416
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
Gonzalo-Gil E; Ikediobi U; Sutton RE
Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
[TBL] [Abstract][Full Text] [Related]
27. HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.
Papasavvas E; Moore EC; Sun J; Azzoni L; Pistilli M; Mounzer K; Shull J; Kostman JR; Montaner LJ
AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1203-8. PubMed ID: 18788911
[TBL] [Abstract][Full Text] [Related]
28. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.
Hatano H; Yukl SA; Ferre AL; Graf EH; Somsouk M; Sinclair E; Abdel-Mohsen M; Liegler T; Harvill K; Hoh R; Palmer S; Bacchetti P; Hunt PW; Martin JN; McCune JM; Tracy RP; Busch MP; O'Doherty U; Shacklett BL; Wong JK; Deeks SG
PLoS Pathog; 2013; 9(10):e1003691. PubMed ID: 24130489
[TBL] [Abstract][Full Text] [Related]
29. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
Jilg N; Garcia-Broncano P; Peluso M; Segal FP; Bosch RJ; Roberts-Toler C; Chen SMY; Van Dam CN; Keefer MC; Kuritzkes DR; Landay AL; Deeks S; Yu XG; Sax PE; Li JZ;
J Infect Dis; 2020 Nov; 222(11):1837-1842. PubMed ID: 32496516
[TBL] [Abstract][Full Text] [Related]
30. HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.
Landay A; Golub ET; Desai S; Zhang J; Winkelman V; Anastos K; Durkin H; Young M; Villacres MC; Greenblatt RM; Norris PJ; Busch MP;
AIDS; 2014 Mar; 28(5):739-43. PubMed ID: 24326356
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
[TBL] [Abstract][Full Text] [Related]
32. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.
Desai SN; Dodge JL; Landay AL; Glesby MJ; Latham PS; Villacres MC; French AL; Gange SJ; Greenblatt RM; Peters MG
Medicine (Baltimore); 2016 Aug; 95(33):e4483. PubMed ID: 27537569
[TBL] [Abstract][Full Text] [Related]
33. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
[TBL] [Abstract][Full Text] [Related]
34. d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.
Porter BO; Ouedraogo GL; Hodge JN; Smith MA; Pau A; Roby G; Kwan R; Bishop RJ; Rehm C; Mican J; Sereti I
Clin Immunol; 2010 Jul; 136(1):42-50. PubMed ID: 20227921
[TBL] [Abstract][Full Text] [Related]
35. Impaired Nef function is associated with early control of HIV-1 viremia.
Kuang XT; Li X; Anmole G; Mwimanzi P; Shahid A; Le AQ; Chong L; Qian H; Miura T; Markle T; Baraki B; Connick E; Daar ES; Jessen H; Kelleher AD; Little S; Markowitz M; Pereyra F; Rosenberg ES; Walker BD; Ueno T; Brumme ZL; Brockman MA
J Virol; 2014 Sep; 88(17):10200-13. PubMed ID: 24965469
[TBL] [Abstract][Full Text] [Related]
36. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.
Pereyra F; Addo MM; Kaufmann DE; Liu Y; Miura T; Rathod A; Baker B; Trocha A; Rosenberg R; Mackey E; Ueda P; Lu Z; Cohen D; Wrin T; Petropoulos CJ; Rosenberg ES; Walker BD
J Infect Dis; 2008 Feb; 197(4):563-71. PubMed ID: 18275276
[TBL] [Abstract][Full Text] [Related]
37. Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals.
Caetano DG; Ribeiro-Alves M; Hottz ED; Vilela LM; Cardoso SW; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bozza PT; Guimarães ML; Côrtes FH
Sci Rep; 2022 Apr; 12(1):6569. PubMed ID: 35449171
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels.
Porter BO; Shen J; Kovacs JA; Davey RT; Rehm C; Lozier J; Csako G; Nghiem K; Costello R; Lane HC; Sereti I
AIDS; 2009 Sep; 23(15):2015-9. PubMed ID: 19617815
[TBL] [Abstract][Full Text] [Related]
39. Low level of regulatory T cells and maintenance of balance between regulatory T cells and TH17 cells in HIV-1-infected elite controllers.
Brandt L; Benfield T; Mens H; Clausen LN; Katzenstein TL; Fomsgaard A; Karlsson I
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):101-8. PubMed ID: 21407087
[TBL] [Abstract][Full Text] [Related]
40. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.
Boulware DR; Hullsiek KH; Puronen CE; Rupert A; Baker JV; French MA; Bohjanen PR; Novak RM; Neaton JD; Sereti I;
J Infect Dis; 2011 Jun; 203(11):1637-46. PubMed ID: 21592994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
